|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Improve Insulin Sensitivity in Pre-Diabetic Individuals
Submitted By Pure Encapsulations New clinical trial shows uniquelyderived strawberry and cranberry polyphenols may improve insulin sensitivity for people with pre-diabetes. Researchers at the Institute of Nutrition and Functional Foods (INAF) at Laval University have found a potential new approach to help people with pre-diabetes stave off the progression of this chronic disease. In a study from the British Journal of Nutrition, GlucoPhenol®, a proprietary blend of cranberry and Orléans strawberry extracts, produced significant improvements in insulin sensitivity among non-diabetic, insulin-resistant adults. Globally, 415 million adults are living with type 1 diabetes and these numbers are projected to grow to 592 million by 2035— affecting one in every ten adults. According to the most recent data from the American Diabetes Association, in the United States alone, an estimated 29.1 million adults have diabetes, while another 86 million are classified as type 2 pre-diabetic. The research team at INAF, led by Hélène Jacques, PhD, undertook the study to determine the effects of polyphenols from strawberries and cranberries on insulin sensitivity, glucose tolerance, and insulin secretion in insulin-resistant men and women who are overweight or obese, but otherwise healthy. "Our data indicate that GlucoPhenol may improve insulin sensitivity and prevent an increase in compensatory insulin secretion, representing a promising approach to improving glucose management in subjects at risk for type 2 diabetes," explained Jacques. "These results are particularly encouraging, as they indicate that polyphenols may delay or even halt the progression to type 2 diabetes." The findings suggest that the cranberry and strawberry polyphenols found in GlucoPhenol may increase both insulin signaling and the transport of glucose into skeletal muscle, thus improving insulin sensitivity. Larger and longer-term studies will be needed, along with controlled dose-response trials to determine the lower and upper range of activity of these polyphenols. "This latest research represents another significant advancement resulting from Pure Encapsulations' collaboration with the Institute of Nutrition and Functional Foods (INAF)," explained Barry Ritz, Chief Scientific Officer for Atrium Innovations. "We have already incorporated the findings from this study into Atrium Innovations products and are committed to continued research to fuel innovation that will improve health outcomes for patients." While berries, such as strawberries and cranberries, are often referred to as "superfoods" and have numerous health benefits, the bioavailability of bioactive polyphenols in whole foods have been shown to be relatively poor. In the current study, however, the concentration of four active polyphenol compounds and metabolites from GlucoPhenol are most likely responsible for the observed benefits that were identified and measured in the blood of study participants. The GlucoPhenol used in the study consists of a proprietary blend of cranberry and Orléans strawberry extracts from North American farms and developed specifically by the study partners. This study is part of a multi-year research collaboration between INAF and Atrium Innovations, which is exploring the impact of lifestyle and nutritional interventions on cardiometabolic health. In addition to polyphenols, researchers have also explored clinical applications of fish oil, systemic enzymes, and their role in improving cardiometabolic health outcomes. REFERENCES: Cardona F, Andrés-Lacueva C, Tulipani S et al, "Benefits of Polyphenols on Gut Microbiota and Implications in Human Health," J Nutr Biochem 24 (2013), 1415–1422. *These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
